1. PRESCRIBING INFORMATION
  2. IMPORTANT SAFETY INFORMATION
  3. FOR PATIENTS
  4. SIGN UP
  • Prescribing Information
  • IMPORTANT SAFETY INFORMATION
  • FOR PATIENTS
  • SIGN UP
Prescribing Information
IMPORTANT SAFETY INFORMATION
FOR PATIENTS
SIGN UP
Logo for Velphoro(R) (sucroferric oxyhydroxide) chewable tablets, the most potent phosphate binder.
  1. POTENCY
  2. EFFICACY
  3. FLEXIBILITY
  4. TOLERABILITY
  5. ACCESS
  6. RESOURCES
  7. CLINICAL CARE TEAM
  8. FOR PATIENTS
  9. PRIVACY
  10. TERMS OF USE
  11. NOTICE OF PRIVACY PRACTICES
  12. PRESCRIBING INFORMATION
  13. CONTACT US
  14. SITE MAP
  • POTENCY
  • EFFICACY
  • FLEXIBILITY
  • TOLERABILITY
  • ACCESS
  • RESOURCES
  • CLINICAL CARE TEAM
  • For Patients
  • Privacy Notice
  • Terms of Use
  • Notice of Privacy Practices
  • Prescribing Information
  • Contact Us
  • Site Map
POTENCY
EFFICACY
FLEXIBILITY
TOLERABILITY
ACCESS
RESOURCES
CLINICAL CARE TEAM
For Patients
Privacy Notice
Terms of Use
Notice of Privacy Practices
Prescribing Information
Contact Us
Site Map

VELPHORO HEALTH CARE PROFESSIONALS SITEMAP

Image of healthcare provider and patient pointing to a V-shaped magnet
  • Home
  • Potency
  • Efficacy
  • Flexibility
  • Tolerability
  • Access
  • Resources
  • Clinical Care Team
  • Register for Information

You are now leaving velphorohcp.com

CONTINUE

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional Safety Information, please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care Customer Service at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals
  1. PRIVACY NOTICE
  2. TERMS OF USE
  3. PRESCRIBING INFORMATION
  4. CONTACT US
  5. SITEMAP
  • PRIVACY NOTICE
  • TERMS OF USE
  • PRESCRIBING INFORMATION
  • CONTACT US
  • SITEMAP
PRIVACY NOTICE
TERMS OF USE
PRESCRIBING INFORMATION
CONTACT US
SITEMAP

© 2021, 2025 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks for which Fresenius Medical Care AG holds rights. Velphoro is a trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners.

Do Not Sell or Share My Personal Data • Limit the Use of My Sensitive Personal Information • Consumer Health Data Privacy Policy

close-icon
close-icon